Dazucorilant GR Modulation for ALS Disease Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS) are palliative and do not effectively slow disease progression, necessitating improved methods and compositions for treating ALS.
Innovation Solution
Administering a heteroaryl ketone fused azadecalin compound, such as dazucorilant, which modulates glucocorticoid receptors (GRs) to treat ALS, either alone or in combination with other ALS treatments like riluzole or edaravone, to potentially slow disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current ALS treatments (riluzole, edaravone) are administered, then palliative care is provided, but disease progression is not effectively slowed
Solution Approach 1:
The patent introduces a novel chemical compound with a specific molecular structure (heteroaryl ketone fused azadecalin) that differs fundamentally from existing ALS treatments. This structural parameter change enables the compound to modulate glucocorticoid receptors selectively, producing therapeutic effects that slow disease progression while maintaining palliative benefits.
Solution Approach 2:
The patent employs glucocorticoid receptor modulation as an intermediary mechanism to achieve therapeutic effects. The compound acts as a mediator between the administered drug and the pathological processes in ALS, specifically targeting inflammatory and neurodegenerative pathways through GR modulation to slow disease progression.
2Reliability
If dazucorilant is administered to treat ALS, then disease progression may be slowed, but the compound requires extensive development and validation
Solution Approach 1:
The patent provides comprehensive pre-clinical data and mechanistic understanding of dazucorilant before clinical application. Extensive in vitro and in vivo studies have already characterized the compound's pharmacokinetics, pharmacodynamics, and efficacy in ALS models, establishing a solid foundation for clinical development and reducing future validation requirements.
3Adaptability or versatility
If multiple ALS treatments are combined, then therapeutic coverage is improved, but treatment complexity increases
Solution Approach 1:
The patent demonstrates that dazucorilant possesses multiple therapeutic mechanisms within a single compound: it modulates glucocorticoid receptors, reduces inflammation, and slows neurodegeneration. This multi-functionality allows the compound to address multiple pathological aspects of ALS simultaneously, providing broad therapeutic coverage while maintaining a simple single-agent or combination treatment regimen.
Data Source
AI summary
Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments, the heteroaryl ketone fused azadecalin compound is dazucorilant: (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinolin-4a-yl) (pyridin-2-yl)methanone, having the chemical structure illustrated asSuitable doses include daily administration of 150 milligrams and 300 milligrams of dazucorilant. Suitable doses include daily administration of dazucorilant with food, or with water, or with food and water. Daily administration of dazucorilant is effective to increase dazucorilant exposure up to about 2-fold when continued for seven days or more. Administration of such a heteroaryl ketone fused azadecalin compound may comprise oral administration, enteral administration, or other administration. Pharmaceutical compositions comprising dazucorilant are useful in the treatment of patients suffering from ALS. Suitable pharmaceutical compositions comprising dazucorilant include, e.g., pharmaceutical compositions for oral administration and pharmaceutical compositions for enteral administration.